三生國健(688336.SH):選取NM28作為新型多特異抗體合作領域首個授權產品
格隆匯12月14日丨三生國健(688336.SH)公佈,近日,公司根據2019年與Numab簽署的合作協議,選取NM28作為新型多特異抗體合作領域首個授權產品,公司擁有NM28在中國大陸、香港、澳門和台灣的開發及商業化專有許可權。
NM28是潛在最優的靶向MSLN的CD3 T cell engager,屬於下一代的T cell engager,主要用於治療間皮瘤。NM28基於Numab的MATCHTM-4平台,該平台允許與間皮素進行二價相互作用,因此具有比傳統T cell engager更大的治療窗口。NM28由四個針對MSLN、CD3和人血清白蛋白(HSA)的穩定化和人源化的抗體可變域片段組成。MSLN通常在多種腫瘤細胞中表達,包括間皮瘤、肺癌、膽道癌、卵巢癌、乳腺癌和胰腺癌。NM28能與高表達MSLN的腫瘤細胞表面更穩定結合,從而能更好地抵禦從腫瘤細胞脱落的可溶性MSLN的干擾,以達到提高療效的作用,並且與單價靶向MSLN的T cell engager相比,NM28能夠更好區分腫瘤細胞和低表達MSLN的正常細胞,安全性更高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.